This hypothesis is further supported by our results that the reduction of ATAD3A dimers and subsequent ATAD3A/Drp1 binding by treatment with DA1 suppressed mitochondrial fragmentation and mtDNA damage, and reduced HD neuropathology. Here, ATAD3A is linked to Huntington disease.